Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia
Expert Review of Pharmacoeconomics & Outcomes Research · 2024
DOI: 10.1080/14737167.2024.2382976 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Pieralessandro Lasalvia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departamento economía de la salud, Neuroeconomix, Bogotá, Colombia. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Benzhydryl Compounds, Renal Insufficiency, Chronic, Glucosides. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca Colombia.
Abstract (Originalsprache)
BACKGROUND: The DAPA-CKD study showed that dapagliflozin added to standard treatment reduced the risk of chronic kidney disease progression, and death from renal or cardiovascular causes compared to placebo. OBJECTIVE: Assess the cost-effectiveness of dapagliflozin and standard treatment versus standard treatment alone for chronic kidney disease within the Colombian health system. METHODS: We employed a Markov model based on the DAPA-CKD study, tailored to the Colombian scenario. The model forecasted hospitalizations for heart failure, overall and cardiovascular mortality, and chronic kidney disease progression over a 10-year horizon with a 5% discount rate. RESULTS: Dapagliflozin combined with standard treatment is a cost-effective intervention in treating stage 2-4 CKD. In the base case, the ICER was US $5,366, below 1 GDP (US $6.558) per capita. This was consistent in the sensitivity analyses. CONCLUSION: Our study showed that dapagliflozin, when combined with standard treatment, is cost-effective against standard treatment alone, aligning with Colombia's willingness-to-pay threshold.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento economía de la salud, Neuroeconomix, Bogotá, Colombia.
- Médico Internista - Nefrólogo. Presidente ACMI (Asociación Colombiana Medicina Interna), Bogotá, Colombia.
- Nefróloga, Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogotá, Colombia.
Förderung
- AstraZeneca Colombia
Zitieren
APA
Lasalvia, P., Vásquez M, E. C., Arango Álvarez, J. J., & Garcia-Padilla, P. (2024). Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2382976
Vancouver
Lasalvia P, Vásquez M EC, Arango Álvarez JJ, Garcia-Padilla P. Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2024.2382976
BibTeX
@article{Lasalvia2024,
author = {Lasalvia, Pieralessandro and Vásquez M, Eliana C and Arango Álvarez, Jose Javier and Garcia-Padilla, Paola},
title = {Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2024},
doi = {10.1080/14737167.2024.2382976}
}
EUVIMED